-
1 month ago | 
insights.citeline.com | Barnaby Pickering
Handheld Diagnostics: A Resurging Category That is Here to StayHandheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
-
1 month ago | 
insights.citeline.com | Barnaby Pickering
Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development. Ex-FDA Commissioner Robert Califf said current administration policies could make vaccine development financially unviable. • Source: Alamy
-
1 month ago | 
insights.citeline.com | Barnaby Pickering
Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA StaffIn Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit. • Source: Reagan-Udall Foundation online event
-
1 month ago | 
insights.citeline.com | Barnaby Pickering
In Conversation: “Decimated” FDA Teams Endanger Biologics Progress, Califf SaysIn Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit. Ex-FDA Comissioner Robert Califf • Source: Alamy
-
2 months ago | 
insights.citeline.com | Barnaby Pickering
Diagnostics Are Essential, But How Can Companies Ensure A Fair Price? Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?
-
Feb 4, 2025 | 
insights.citeline.com | Barnaby Pickering
As The Dust Settles, What Can We Learn From The J&J Vs. Auris Case? 04 Feb 2025 • By Barnaby PickeringIn September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.
-
Jan 17, 2025 | 
insights.citeline.com | Barnaby Pickering
Genetic Analysis Leaders On Gut Microbiota Testing, Pharma Connections And Direct-To-Consumer SceneGenetic Analysis CEO Ronny Hermansen and Christina Casén, senior VP of clinical and medical affairs, discuss the company’s polymerase chain reaction (PCR)-based approach to gut microbiota profiling versus DNA sequencing, competitive landscape, and opportunities for supporting pharma R&D and assessing drug treatment success.
-
Jan 2, 2025 | 
insights.citeline.com | Barnaby Pickering
When It Comes To Spine, Incumbents Are ‘Not Listening To Surgeons,’ Says Spineart CEO Jerome TrividicJerome Trividic, CEO of Swiss company Spineart, believes that by solving pain points felt by orthopedic surgeons performing spinal procedures, it can improve patient outcomes. He thinks the firm’s innovative approach, which focuses on partnership deals as well as developing its own products, will give it a competitive edge in the spinal surgery market.
-
Jan 1, 2025 | 
insights.citeline.com | Barnaby Pickering
La French Touch: How France Has Built a Reputation for Excellence In MedtechFrance’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.
-
Dec 18, 2024 | 
insights.citeline.com | Barnaby Pickering
Device-Activated Drugs, An Old Dog With Some New TricksAs technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. In Vivo spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.
